威尼斯在线平台-澳门威尼斯网站登录

?
注射用血栓通对比银杏达莫注射液治疗缺血性脑卒中的成本-效果分析
在线阅读 >
x

请在关注微信后,向客服人员索取文件

篇名: 注射用血栓通对比银杏达莫注射液治疗缺血性脑卒中的成本-效果分析
TITLE:
摘要: 目的:比较注射用血栓通与银杏达莫注射液治疗缺血性脑卒中的疗效和经济性。方法:回顾性分析404例缺血性脑卒中患者资料,按用药不同分为血栓通组(271例)和银杏达莫组(133例)。两组患者在常规治疗基础上分别使用注射用血栓通和银杏达莫注射液治疗。两组患者平均疗程均为10 d。以总有效率作为疗效指标,比较两种治疗方案的疗效和经济性。结果:血栓通组和银杏达莫组患者总有效率分别为90.77%、88.72%,两组比较差异无统计学意义(P>0.05);两组治疗方案成本分别为12 860.21元、13 155.40元,血栓通组低于银杏达莫组。结论:注射用血栓通和银杏达莫注射液治疗缺血性脑卒中的疗效均较好,但注射用血栓通的经济性更佳。
ABSTRACT: OBJECTIVE: To compare pharmacoeconomic and effect of Xueshuantong for injection and Ginkgo leaf extract and dipyridamole injection in the treatment of ischemic stroke. METHODS: Retrospective study was conducted. Totally 404 inpatients with ischemic stroke were divided into Xueshuantong group (271 cases) and ginkgo leaf extract and dipyridamole group (133 cases) according to clinical treatment programs. Based on the conventional treatment, patients in 2 groups were given Xueshuantong for injection and ginkgo leaf extract and dipyridamole injection, respectively. The average treatment course was 10 d. Cost-minimization analysis was performed with the determination index of total effective rate. RESULTS: The total effective rates in Xueshuantong group and ginkgo leaf extract and dipyridamole group were 90.77% and 88.72%, respectively, the difference was not statistically significant(P>0.05). The costs in 2 groups were 12 860.21 yuan and 13 155.40 yuan, respectively, and xueshuantong group had lower than ginkgo leaf extract and dipyridamde group. CONCLUSIONS: Both  Xueshuantong for injection and Ginkgo leaf extract and dipyridamole injection are effective in the treatment of ischemic stroke. However, the economy of Xueshuantong for injection is superior to the other one.
期刊: 2015年第26卷第36期
编辑: 高琲,孟敏,于静,萨日娜,杨岩,葛斌,赵洪儒
AUTHORS: GAO Bei,MENG Min,YU Jing,SA Ri-na,YANG Yan,GE Bin,ZHAO Hong-ru
关键字: 注射用血栓通;银杏达莫注射液;缺血性脑卒中;成本-效果分析
KEYWORDS: Xueshuantong injection; Ginkgo leaf extract and dipyridamole injection; Ischemic stroke; Cost-effectiveness analysis
阅读数: 265 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支撑与合作!

?